


# UBS Asian Equities Fund USD

## Performance Review

UBS (Lux) Key Selection SICAV - Asian Equities (USD) I-A1-acc



### Performance (basis USD, net of fees)<sup>1</sup>



**Past performance is not a reliable indicator of future results.**

### Performance in %<sup>1</sup>

in %	2020	2021	2022	2023	2024 YTD <sup>2</sup>	LTD <sup>3</sup>	3 years Ø p.a. 3 years
Fund (USD)	n.a.	-5.26	-25.95	9.83	7.76	-11.98	-4.60
Benchmark <sup>4</sup>	n.a.	-4.72	-19.67	5.98	15.59	-1.50	-1.39

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

<sup>3</sup> LTD: launch-to-date

<sup>4</sup> Reference Index in currency of share class (without costs)

**Asian equities fell on concerns over higher-for-longer fed funds rates amid robust US economic data. In addition, the possibility of a Trump election win looked more likely. India fell the most as earnings continued to disappoint. Sector-wise, IT was the only sector with positive returns, while energy was the biggest detractor.**

### Monthly performance

In October the fund performed negatively with 3.0%. In terms of sectors, industrials and information technology were key contributors, while financials detracted the most. Market-wise, Taiwan and India were key contributors, while China detracted.

### YTD performance

YTD as of the end of October, the fund has delivered a positive performance of 7.8%. Sector-wise, consumer discretionary, IT and financials have been key detractors, while materials and industrials contributed the most. In terms of markets, China and India have been key detractors, while Malaysia has been the biggest contributor.

### Performance contributors

Shenzhen Megmeet was the key contributor on positive sentiment towards its collaboration with NVIDIA regarding power supply for AI servers. NVIDIA confirmed that it had fixed its issue with Blackwell AI chips, which had impacted yield, and that shipments would accelerate.

### Performance detractors

Ping An Insurance detracted the most in October as the stock corrected when the stimulus-induced rally faded. We believe the company has stable insurance operations following its agency reform and is seeing growing contributions from the bancassurance channel, despite macro weakness. Investors' confidence in Ping An's balance sheet was strengthened as government policies are aimed at stabilising the economy and stemming the real estate market's decline.

### For more information

**UBS Fund Infoline: 0800 899 899**

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Shou Pin Choo

Raymond Wong

Projit Chatterjee

# UBS Asian Equities Fund USD

## Market exposure (%)

	Fund	Deviation from index
China	29.15	-2.0
Taiwan	26.48	+4.8
India	19.07	-2.4
Republic of Korea	11.43	-0.0
Malaysia	3.18	+1.5
Singapore	2.98	-0.6
Philippines	1.52	+0.9
Hong Kong	1.30	-3.5
United States	0.75	+0.8
Others	4.14	+0.6

## Sector exposure (%)

	Fund	Deviation from index
Information Technology	37.09	+10.3
Financial Services	21.65	+0.3
Communication Services	12.54	+2.9
Consumer Discretionary	8.82	-5.6
Industrials	4.52	-2.9
Cash	4.16	
Consumer Staples	3.20	-0.8
Real estate	3.13	+0.8
Energy	2.75	-0.7
Health Care	1.21	-2.4
Utility	0.93	-1.8
Materials	0.00	-4.2

## 10 largest equity positions (%)<sup>1</sup>

	Fund
Taiwan Semiconductor Manufacturing Co Ltd	9.8
Tencent Holdings Ltd	8.7
Ping An Insurance Group Co of China Ltd	5.0
Samsung Electronics Co Ltd	4.7
HDFC Bank Ltd	4.7
SK Hynix Inc	4.3
Hon Hai Precision Industry Co Ltd	3.8
PDD Holdings Inc	3.6
MediaTek Inc	3.4
Axis Bank Ltd	3.2

<sup>1</sup> This is not a recommendation to buy or sell any security

## Current investment strategy

We increased our China exposure shortly after month-end, narrowing our underweight by adding to what are still attractively-valued names. We will continue to monitor the execution of the policies that the Chinese government has announced and may add at times when the operating environment and earnings could be turning.

## Risks

UBS Key Selection Equity Funds invest in equities and may therefore be subject to high fluctuations in value. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.